Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/04/2839511/0/en/Elixirgen-Therapeutics-Presents-Preclinical-Data-with-Bobcat-mRNATM-Technology-in-Duchenne-Muscular-Dystrophy-at-the-2024-Muscular-Dystrophy-Association-MDA-Clinical-Scientific-Con.html
https://www.globenewswire.com//news-release/2023/10/16/2760576/0/en/Elixirgen-Therapeutics-Announces-Promising-Phase-1-2-Data-on-EXG-5003-a-Controllable-Self-Replicating-RNA-c-srRNA-Vaccine-Against-SARS-CoV-2.html
https://www.globenewswire.com/news-release/2023/01/26/2595987/0/en/Elixirgen-Therapeutics-Enters-Memorandum-of-Understanding-with-Hitachi-Global-Life-Solutions-for-the-Development-of-Micro-GMP-Suites-for-Cell-Therapy-Administration.html
https://www.globenewswire.com//news-release/2023/01/04/2582839/0/en/Elixirgen-Therapeutics-to-Attend-the-2023-Biotech-Showcase-Conference.html
https://www.globenewswire.com//news-release/2022/12/21/2577841/0/en/Elixirgen-Therapeutics-Appoints-Jeffrey-L-Cleland-Ph-D-to-Board-of-Directors.html
https://www.globenewswire.com//news-release/2022/12/12/2572138/0/en/Elixirgen-Therapeutics-Presents-New-Clinical-Data-Demonstrating-Ex-Vivo-Telomere-Elongation-with-EXG-34217-in-Dyskeratosis-Congenita-at-the-64th-ASH-Annual-Meeting.html
https://www.globenewswire.com/news-release/2022/11/07/2549610/0/en/Elixirgen-Therapeutics-to-Present-New-Data-Showing-Successful-Ex-Vivo-Telomere-Elongation-with-EXG-34217-in-a-Phase-1-2-Clinical-Trial-at-the-64th-ASH-Annual-Meeting.html
https://www.prnewswire.com/news-releases/elixirgen-therapeutics-partners-with-taisho-pharmaceutical-on-therapeutics-for-aging-associated-diseases-301496531.html
https://www.prnewswire.com/news-releases/elixirgen-therapeutics-announces-dosing-of-first-and-second-participants-in-its-covid-19-vaccine-phase-12-clinical-trial-at-fujita-health-university-301298735.html